CRISPR Therapeutics AG. (10/2/18). "Press Release: CRISPR Therapeutics to Present at the Chardan Genetic Medicines Conference". Zug & Cambridge, MA.

	Organisation	CRISPR Therapeutics AG (Nasdaq: CRSP)
	Group	CRISPR Therapeutics (Group)
	Organisation 2	Chardan Capital Markets LLC
	Product	Chardan Genetic Medicines Conference 2018 New York
	Product 2	CRISPR gene editing technology
	Index term	CRISPR Therapeutics–Chardan: investor conference, 201810 supply service CRISPR presents at Chardan Genetic Medicines Conference in New York
	Person	Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
	Person 2	Kim, Susan (CRISPR Therapeutics 201809 Investor Relations)

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer, will present at the Chardan Genetic Medicines Conference on Tuesday, October 9, 2018 at 11:30 am ET.

A live webcast of the Chardan presentation will be available on the "Events & Presentations" page in the Investors section of the company's website at https://crisprtx.com/events. A replay of the webcast will be archived on the company's website for 14 days following the presentation.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc.

CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR Investor Contact:
Susan Kim
susan.kim@crisprtx.com

CRISPR Media Contact:
Jennifer Paganelli
WCG on behalf of CRISPR
347-658-8290
jpaganelli@wcgworld.com

Record changed: 2018-10-13